Michael Berman is a medical device investor/entrepreneur who serves on the boards of 11 emerging medical companies.
Mr. Berman was a co-founder of Velocimed which was sold to St. Jude Medical in April, 2005 for $82.5M.
Mr. Berman was a Director of Lutonix from 2007 until 2011 when it was sold to CR Bard for $225M, plus $100M upon FDA approval.
Mr. Berman was a co-founder and Chairman of BridgePoint Medical from 2005 till 2012 when it was sold to Boston Scientific.
Mr. Berman was a director of UltraShape inc. from 2005 till 2011 when it was sold to Syneron.
From 1995-2000 Mr. Berman was the President of the Cardiology business of Boston Scientific.
Cornell University, BS, 1979
Cornell University, MBA, 1986